Filter posts

Beyond the IPO: Reverse Mergers to Tap Public Market Capital

On the opening day of the 2017 BIO CEO & Investor Conference in New York …

The Bio Report: What a Decade of Investment Tells Us About the Health of Biotech

In this podcast, The Bio Report’s Daniel Levine interviews BIO’s Dave Thomas on the recent …

Blurred Lines: Investors Explain Their Re-Thinking of Traditional Private-Only or Public-Only Invest...

The recent expansion and acceleration of the biotech stock market has seen a new willingness …

Biotech CEOs Speak Out on JOBS Act Success

Enacted in April 2012, the Jumpstart Our Business Startups (JOBS) Act makes the pathway to …

Debunking the Biotech Bubble Talk

The Nasdaq Biotechnology Index (NBI) has been on a wild ride in 2014 with a …

San Francisco Business Times: Two JOBS Acts are better than one

Today, the San Francisco Business Times published an op-ed by OncoMed President and CEO Paul Hastings lauding …

#BIOCEO14: An Optimistic Outlook for 2014

The 16th Annual BIO CEO & Investor Conference​ concluded with a lively Closing Plenary Session examining …

What’s Behind the Biotech IPO Boom?

Everyone knows that it’s been a knock-out year for the biotech sector in the public …

Lots of Buzz at the BIO Investor Forum

Thirty-eight biotech IPO’s this year. The NASDAQ Biotechnology Index is up 50 percent YTD.  Are …

The New Road to IPO in the Age of the JOBS Act

Not surprisingly, sessions discussing the topic of IPOs at this year’s BIO Investor Forum, tend …